ASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS

Similar documents
Introduction to Chemoinformatics and Drug Discovery

Advanced Medicinal Chemistry SLIDES B

Structural biology and drug design: An overview

Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry

Lead- and drug-like compounds: the rule-of-five revolution

FRAUNHOFER IME SCREENINGPORT

Using AutoDock for Virtual Screening

Computational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004

ADME SCREENING OF NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES

COMPUTER AIDED DRUG DESIGN (CADD) AND DEVELOPMENT METHODS

Hydrogen Bonding & Molecular Design Peter

Plan. Day 2: Exercise on MHC molecules.

Flow of information in a drug discovery pipeline. 7th lecture Modern Methods in Drug Discovery WS16/17 1

Receptor Based Drug Design (1)

Enamine Golden Fragment Library

PHYSIO-CHEMICAL PROPERTIES OF THE DRUG. It is the interaction of the drug with its environment

Plan. Lecture: What is Chemoinformatics and Drug Design? Description of Support Vector Machine (SVM) and its used in Chemoinformatics.

Dongyue Cao,, Junmei Wang,, Rui Zhou, Youyong Li, Huidong Yu, and Tingjun Hou*,, INTRODUCTION

Rules for drug discovery: can simple property criteria help you to find a drug?

Alkane/water partition coefficients and hydrogen bonding. Peter Kenny

Evolution of toxic properties of Anti Alzheimer s Drugs through Lipinski s rule of five

Synthetic organic compounds

In silico pharmacology for drug discovery

Comparison of log P/D with bio-mimetic properties

In silico Assessment of Drug-like Properties of Alkaloids from Areca catechu L Nut

Multi-Parameter Optimization: Identifying high quality compounds with a balance of properties

Quantitative structure activity relationship and drug design: A Review

Supporting Information (Part II) for ACS Combinatorial Science

Medicinal Chemistry/ CHEM 458/658 Chapter 3- SAR and QSAR

Chemical library design

Quantum Mechanical Models of P450 Metabolism to Guide Optimization of Metabolic Stability

CNS-Targeted Library

Relative Drug Likelihood: Going beyond Drug-Likeness

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Introduction. OntoChem

Site-Specific Prodrug Release Using Visible Light

György M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences

Early Stages of Drug Discovery in the Pharmaceutical Industry

Computational Models for the Prediction of Intestinal Membrane Permeability

Drug Design 2. Oliver Kohlbacher. Winter 2009/ QSAR Part I: Motivation, Basics, Descriptors

Open PHACTS Explorer: Compound by Name

A Picture Paints a Thousand Words Visualisation of SAR. John Cumming, AstraZeneca, Alderley Park, UK

Correspondence should be addressed to M. G. Shambhu;

CH MEDICINAL CHEMISTRY

TRAINING REAXYS MEDICINAL CHEMISTRY

Drug Discovery. Zainab Al Kharusi Office: 33-10

Translating Methods from Pharma to Flavours & Fragrances

Keywords: anti-coagulants, factor Xa, QSAR, Thrombosis. Introduction

Introduction to medicinal chemisry

Nonlinear QSAR and 3D QSAR

CHAPTER - I' APP1ICATlON OF LIPINSKI RULE OF FIVE

Building predictive unbound brain-to-plasma concentration ratio (K p,uu,brain ) models

Data Quality Issues That Can Impact Drug Discovery

Synthetic organic compounds

PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

QMRF identifier (JRC Inventory): QMRF Title: QSAR model for blood-brain barrier (BBB) partition Printing Date:

Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses

Effect of 3D parameters on Antifungal Activities of Some Heterocyclic Compounds

Data Mining in the Chemical Industry. Overview of presentation

1. (18) Multiple choice questions. Please place your answer on the line preceding each question.

Medicinal Chemistry 1

Unlocking the potential of your drug discovery programme

Comparing Multi-Label Classification Methods for Provisional Biopharmaceutics Class Prediction

CHEM 4170 Problem Set #1

Applying Bioisosteric Transformations to Predict Novel, High Quality Compounds

Principles of Drug Design

Considering the Impact of Drug-like Properties on the Chance of Success

Literature Review: Heterocyclic compounds are of particular interest in medicinal chemistry. The chemistry of heterocyclic compounds is one of the

Delivery. Delivery Processes. Delivery Processes: Distribution. Ultimate Toxicant

ADME Evaluation in Drug Discovery. 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine

Course Specification Medicinal Chemistry-1

Comparing Multilabel Classification Methods for Provisional Biopharmaceutics Class Prediction

CHEMISTRY (CHE) CHE 104 General Descriptive Chemistry II 3

International Journal of Pharma and Bio Sciences CONCEPT OF DRUG LIKENESS IN PHARMACEUTICAL RESEARCH ABSTRACT

Lead Optimization Studies on Novel Quinolones Derivatives as CYP-450 Inhibitor by using In-Silico Modulation

AMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE

Dr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre

Design and Synthesis of the Comprehensive Fragment Library

(Syllabus): ORGANIC PHARMACEUTICAL CHEMISTRY (elective)

Research Journal of Pharmaceutical, Biological and Chemical Sciences

RECENT TRENDS IN PHARMACEUTICAL CHEMISTRY FOR DRUG DISCOVERY

Amorphous Blobs of Hope and Other Flights of Fancy. Steve Muchmore Chemaxon UGM April 18, 2011 Budapest

Opportunities to Incorporate Toxicology into the Chemistry Curriculum Report from the Field

Advances in Multi-parameter Optimisation Methods for de Novo Drug Design

molecules ISSN

Research of New Class C beta-lactamase Inhibitor by Molecular Docking s Method

xxvii ABSTRACT OF THE THESIS

Important Aspects of Fragment Screening Collection Design

Computational chemical biology to address non-traditional drug targets. John Karanicolas

Computational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007

molecules ISSN

Hit to Lead Michael Rafferty

Chapter 10 Manipulating Molecules and Designing Drugs

PHARMA SCIENCE MONITOR

Bioisosterism. A Rational Approach in Drug Design. 刘俊辉 Sept. 30th Sila-majantol 1b. lily-of-the-valley flowers but more terpineol-like odor

Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME

Journal of Chemical and Pharmaceutical Research

PHARMACOKINETIC DERIVATION OF RATES AND ORDERS OF REACTIONS IN MULTI- COMPARTMENT MODEL USING MATLAB

2D-QSAR model development and analysis on variant groups of anti -tuberculosis drugs

October 6 University Faculty of pharmacy Computer Aided Drug Design Unit

Transcription:

Page109 IJPBS Volume 5 Issue 1 JAN-MAR 2015 109-114 Research Article Pharmaceutical Sciences ASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Technology,Sri Padmavathi Mahila Visvavidyalayam (Women s University),Tirupathi 517502,Andhra Pradesh, India. *Corresponding Author Email: shaheen.pharmchem@gmail.com ABSTRACT Chalcones are very well known natural as well as synthetic compounds associated with diverse set of pharmacological activities. They have the potential to be developed as lead compounds for the discovery of antioxidant, anti-inflammatory and anticancer agents. Naturally occurring and synthetic chalcone compounds have shown safety profiles in clinical trials. To study impact of substitutions on drug-likeliness and ADME profile of chalcones, twenty chalcones were selected from literature and molecular properties such as partition coefficient (Log P), molecular weight, number of H-bond acceptors and donors, molecular polar surface area(tpsa) and number of rotatable bonds were calculated using molinspiration software available on the website: http://www.molinspiration.com/cgi-bin/properties.adme profile has been obtained using pre ADMET free online tool (preadmet). Results clearly demonstrated that all chalcones have very good oral absorption and oral bioavailability. It is also observed that 4-acetamido substitution had decreased chalcones permeability in to CNS. In vitro plasma protein binding of 4-acetamido chalcones is less when compared to other chalcones. Compounds 1-20 showed % HIA ranging from 95.58 to 100% and all compounds showed optimum Caco-2 cell permeability (19.15-56.39 nm/sec). Seven out of twenty chalcones (1,2,4,6,7,10,20) displayed optimum MDCK cell permeability (25-500 nm/sec). 4-acetamido group introduction on chalcone had a great impact on the physicochemical and ADME profile of these molecules. KEY WORDS Chalcones, Drug likeliness, Molinspiration, ADME, LogP, MDCK cell permeability, Caco-2 cell permeability, TPSA, preadmet INTRODUCTION Lipinski s Rule of Five (Ro5) which stipulates limits for certain parameters for good oral absorbtion or permeability is considered as the first systemic guidelines in medicinal chemistry [1]. This rule predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the molecular weight (M.Wt) is greater than 500 and the calculated Log P (CLogP) is greater than 5 (or MlogP.4.15)[2].Many related rules have been subsequently modified and proposed as the "Rule-of-Three, which defines fragment properties with an average molecular weight 300 Da, Clog P 3, the number of hydrogen bond donors 3, the number of hydrogen bond acceptors 3, and the number of rotatable bonds < 3. Recently, Pfizer's "Rule of 3/75" has been described which states that compounds with a calculated partition coefficient (ClogP) of < 3 and topological polar surface area (TPSA) > 75 have the best chances of being well tolerated from a safety perspective in vivo[3]. The concept of drug-likeness has been introduced to determine the characteristics necessary for a drug to be successful. It helps to optimize

Page110 pharmacokinetic and pharmaceutical properties, for example, solubility, chemical stability, bioavailability and distribution profile [4]. Druglikeness can be calculated based on the molecular descriptors as per Lipinski s Rule-of-Five. Many in silico tools can be used to design libraries of compounds with drug-like properties [3]. With the use of in silico tools it is possible to predict drug-likeliness and pharmacokinetic or ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profile, drug safety and drug-drug interactions, thereby accelerate the drug discovery process[2]. Chalcone is a versatile template that is linked with several important biological activities such as antioxidant, anticancer, anti-inflammatory, antibacterial, antifungal, antiviral, antitubercular, antimalarial, antileishmanial, antihyperglycemic, activity etc[5]. Chalcones (1, 3-Diphenyl-2- propen-1-one) have a three-carbon α, β- unsaturated carbonyl system and have potential to inhibit enzyme systems [6]. Chalcones have sufficient lipophilicity to cross blood brain barrier and have been proposed to play a useful role in protecting the central nervous system against oxidative and excitotoxic stress [7]. In the present paper twenty chalcones (Table.1) were selected from the literature [8,9]and their drug likeness,adme parameters were predicted using in-silico tools. As much useful and relevant information as possible on the structural features and physicochemical properties of chalcones have been acquired. Influence of various parameters on absorption,metabolism and their ability to penetrate in to brain were reported. MATERIALS AND METHODS Lipinski s rule of five is versatile to evaluate drug likeness properties [10]. Molinspiration, web based software was used to obtain physicochemical properties such as LogP, TPSA, drug likeness (http://www.molinspiration.com/cgibin/properties last accessed on 28th Dec 2015). Log P parameter is used to check good permeability across the cell membrane. Molecular polar surface area (TPSA) is a very useful parameter to predict the transport properties of drugs like intestinal absorption and blood-brain barrier penetration. TPSA and molecular volume is inversely proportional to percentage absorption (%ABS). Therefore, it allows prediction of transport properties of drugs in the intestines and blood-brain barrier crossing. The polar surface area (PSA) of a molecule is a useful descriptor for the optimization of drugs ability to permeate cells.this has been calculated as Topological polar surface area (TPSA), which is recognized as a good indicator of drug absorption in the intestine. Topological polar surface area was used to calculate the percentage of Absorption (%ABS) according to the equation: %ABS =109 [0.345 TPSA] [11]. Number of rotatable bonds measures molecular flexibility and proved to be a very good descriptor of absorption and bioavailbility of drugs. In vitro %HIA, Caco2 and MDCK cell permeabilities, plasma protein binding and bloodbrain barrier penetration values of chalcones were obtained from ADME calculator (http://www.preadmet.bmdc.org/index.php last accessed on 8th Feb, 2015).

Page111 RESULTS AND DISCUSISON All twenty chalcones have very good absorption in the system (Table 1, 2). Drug likeliness is attributed to chalcones when they are substituted with acetamido group at 4 th position. It is evident from Table.3 that all 4-acetamido chalcones have obeyed Lipinski s rule. Clog P of these compounds were found below 5, suggesting good permeability across cell membrane. Two compounds (13, 17) have 6 rotatable bonds that is they have more conformational flexibility than others. All the compounds can easily bind to the receptor as n violatios =1 or <0 for the given set of compounds. It was observed that all the title compounds exhibited good %absorption ranging from 77.26 to 103.11%. Oral drug absorption can be predicted using in vitro models like human intestinal absorption (%HIA), Caco2 cell (PCaco2) and MDCK cell (PMDCK) permeabilities (Table 4, 5). Compounds 1-20 showed % HIA ranging from 95.58 to 100% and all compounds showed optimum Caco2 cell permeability (19.15-56.39 nm/sec). Seven out of twenty chalcones (1,2,4,6,7,10,20) displayed optimum MDCK cell permeability (25-500 nm/sec).except chalcones 13,17,19,20, others have optimum penetration into CNS via the blood-brain barrier.it is also observed that 4-acetamido substitution had decreased chalcones permeability in to CNS. In vitro plasma protein binding of 4-acetamido chalcones is less when compared to other chalcones.it can be concluded that 4-acetamido group introduction on chalcone had a great impact on the physicochemical and ADME profile of these molecules. Table.1 Physicochemical data of chalcones Chalcone R 1 R 2 Melting point 1 4-H 4-H 119-122 2 4-H 3,4(-Cl) 2 96-100 3 4-N(CH 3 ) 2 3,4(-Cl) 2 124-126 4 4-Cl 4-Cl 160-163 5 4-Cl 3,4(-Cl) 2 120-123 6 4-CH 3 4-Cl 159-162 7 4-Cl 4-H 122-125 8 4-Cl 4-Br 168-170 9 4-CH 3 4-H 95.6-100 10 4-H 4-Cl 85-92 11 4-H 4-Br 155-160 12 4-H 4-NHCOCH 3 161.7-162.2 13 4-OCH 3 4-NHCOCH 3 206.5-207 14 4-CH 3 4-NHCOCH 3 197.5-199 15 4-Cl 4-NHCOCH 3 215-215.7 16 3,4(-Cl) 2 4-NHCOCH 3 210.4-211 17 4-NO 2 4-NHCOCH 3 239.7-241 18 4-N(CH 3 ) 2 4-NHCOCH 3 150.9-154.7 19 Thiophene( ring B) 4-NHCOCH 3 147.8-149.3 20 Furan ( ring B) 4-NHCOCH 3 118-119

Page112 Table 2: Prediction of the molecular properties for chalcones and derivatives (1-10) S.No CLogP M.Wt HBA HBD nvio nrotb Volume TPSA %ABS 1 4.082 222.28 1 0 0 4 218.65 17.071 103.11 2 5.366 291.17 1 0 1 4 245.72 17.071 103.11 3 5.468 334.24 2 0 1 5 291.63 20.309 101.99 4 5.438 291.17 1 0 1 4 245.72 17.071 103.11 5 6.044 325.62 1 0 1 4 259.26 17.071 103.11 6 5.208 270.75 1 0 1 4 248.75 17.071 103.11 7 4.76 256.73 1 0 0 4 232.19 17.071 103.11 8 5.569 335.62 1 0 1 4 250.07 17.071 103.11 9 4.53 236.31 1 0 0 4 235.21 17.071 103.11 10 4.76 256.72 1 0 0 4 232.29 17.071 103.11 a)%abs, percentage of absorption; MW, molecular weight; HBD, number of H-bond donors; HBA,number of H-bond acceptors;;nrotb, number of rotatable bonds; nvio.number of violations;tpsa,topological polar surface area. Table 3: Prediction of the molecular properties for chalcones and derivatives (11-20) S.No CLogP M.Wt HBA HBD nvio nrotb Volume TPSA %ABS 11 4.62 287.15 1 0 0 3 219.73 17.071 103.11 12 3.301 279.33 3 1 0 5 266.60 46.169 93.071 13 3.357 309.36 4 1 0 6 292.14 55.403 89.885 14 3.749 293.36 3 1 0 5 283.16 46.169 93.071 15 3.979 313.78 3 1 0 5 280.13 46.169 93.071 16 4.584 348.22 3 1 0 5 293.67 46.169 93.071 17 3.259 324.33 6 1 0 6 289.93 91.993 77.262 18 3.403 322.40 4 1 0 6 312.50 49.407 91.954 19 3.02 285.36 3 1 0 5 257.31 46.169 93.071 20 2.378 269.3 4 1 0 5 248.16 59.309 88.53 b) %ABS, percentage of absorption; MW, molecular weight; HBD, number of H-bond donors; HBA,number of H-bond acceptors;;nrotb, number of rotatable bonds; nvio.number of violations;tpsa,topological polar surface area.

Page113 S.No Table4: ADME properties for chalcones (1-10) In vitro Caco-2 HIA (%) MDCK ippb C brain /C blood 1 54.59 100 115.20 94.83 1.515 2 55.38 100 33.40 95.78 5.52 3 56.39 100 1.93 93.61 6.08 4 56.01 100 37.93 100 6.31 5 55.80 100 8.98 100 2.26 6 54.95 100 48.73 100 5.51 7 55.17 100 54.91 100 2.97 8 55.69 100 0.15 100 2.41 9 55.07 100 0.74 100 6.12 10 54.92 100 54.91 100 2.97 c) PCaco2, Caco2 cell permeability in nm/sec; HIA(%), Percentage human intestinal absorption; PMDCK, Madin-Darby canine kidney cell permeabity in nm/sec; PPB(%), in vitro plasma protein binding (percentage); BBB(Cbrain/Cblood), in vivo Blood-Brain Barrier penetration. Table5: ADME properties for chalcones (11-20) S.No In vitro Caco-2 HIA (%) MDCK ippb C brain /C blood 11 55.05 100 0.575 100 3.38 12 27.34 95.58 12.58 91.35 0.22 13 32.41 95.64 9.66 89.92 0.063 14 28.33 95.69 5.85 90.90 0.48 15 30.51 96.08 4.08 89.15 0.62 16 33.93 96.50 0.28 91.20 1.85 17 19.15 95.85 1.53 87.20 0.012 18 36.92 95.83 0.711 91.77 0.16 19 30.55 96.40 11.41 90.79 0.08 20 31.995 95.59 221.8 84.07 0.027 d) PCaco2, Caco2 cell permeability in nm/sec; HIA(%), Percentage human intestinal absorption; PMDCK, Madin-Darby canine kidney cell permeabity in nm/sec; PPB(%), in vitro plasma protein binding (percentage); BBB(Cbrain/Cblood), in vivo Blood-Brain Barrier penetration.

Page114 REFERENCES 1. Nicolaou K. C., Advancing the Drug Discovery and Development Process. Angew. Chem. Int. Ed, 53: 9128 9140, (2014) 2. Tingjun H., Recent Advances in Computational Prediction of Drug Absorption and Permeability in Drug Discovery. Current Medicinal Chemistry, 13: 2653-2667,(2006) 3. Vistoli G., Assessing drug-likeness What are we missing? Drug Discov. Today, 13: 285-294, (2008). 4. Lavecchia A.,Virtual Screening Strategies in Drug Discovery: A Critical Review. Current Medicinal Chemistry,20:1-22,(2013) 5. Mathewa B., Heteroaryl chalcones: Mini review about their therapeutic voyage. Biomedicine & Preventive Nutrition, 4: 451 458, (2014) 6. Campos-Buzzi F., 4 -Acetamidochalcone Derivatives as Potential Antinociceptive agents.molecules,12: 896-906,(2007) 7. Elmann A, Protective and Antioxidant Effects of a Chalconoid from Pulicaria incisa on Brain Astrocytes. Oxidative Medicine and Cellular Longevity Volume, Article ID 694398:(2013) 8. Rogerio C., Antinociceptive Properties of chalcones. Structure-activity relationships Arch. Pharm. Pharm. Med. Chem, 2001, 334, 332-334, (2001) 9. Cechinel-Filho V., Synthesis of xanthoxyline derivatives with antinociceptive and antioedematogenic activities. Eur.J.Med.Chem, 31:833-839, (1996) 10. Lipinski CA., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev, 23(1-3): 3-25,(1997) 11. Ahsan M.J. Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents. Bio org. Med. Chem. Lett, 21: 7246-7250, (2011). *Corresponding Author: shaheen.pharmchem@gmail.com